Ethics and Transparency Statements

At J.G. Charisis & Company, herein referred to as the “Company”, we uphold the highest standards of integrity and transparency in delivering specialized services to clients in the pharmaceutical and investment sectors. The statements below reflect our unwavering commitment to ethical conduct and client-centric solutions.

Conflict of Interest Disclosure Statement

The Company is dedicated to upholding the highest standards of integrity and objectivity as a premier service provider to clients, encompassing pharmaceutical companies and investors owning pharmaceutical assets. A conflict of interest may occur when personal, financial, or professional interests could potentially influence, or appear to influence, our impartiality in our activities, such as when facilitating transactions or partnerships involving portfolio companies or competing investment interests. We proactively manage such conflicts through a rigorous process that includes mandatory disclosure of any financial ties, affiliations with clients, portfolio companies, competitors, or vendors, and other relevant relationships by our employees, contractors, and partners. Our Company diligently reviews and mitigates conflicts through measures such as recusal, transparent client communication, or divestment of conflicting interests, ensuring adherence to global regulatory standards and industry best practices.

Asset Management and Fiduciary Duty Statement

While we do not engage in direct asset management or investment advisory activities, we are committed to acting in the best interests of our clients when delivering services that support the strategic and commercial enhancement of their pharmaceutical assets. Our approach emphasizes transparency, impartiality, and alignment with client objectives, ensuring that our recommendations and facilitation efforts prioritize client success. We disclose any potential conflicts of interest, as outlined in our Conflict of Interest Policy, and maintain clear communication regarding our service scope and compensation structures. Our practices adhere to global regulatory standards and industry best practices, fostering trust and accountability with all of our clients.

Research Disclosure Statement

The market insights, strategic analyses, and forecasts presented by the Company reflect our professional judgment as of the date of publication and are subject to change without notice. These deliverables, rooted in our expertise in business development services across Europe and North America, rely on assumptions that may vary significantly due to evolving economic, regulatory, market, or competitive conditions within the pharmaceutical and investment sectors. The Company assumes no obligation to update or revise such forecasts or analyses. 

Certain information provided may be derived from third-party sources, believed to be reliable but not independently verified as of the date of publication. The Company and its affiliates disclaim responsibility for the accuracy, completeness, or fairness of such external information. References to specific partnerships, clients, portfolio companies, or market opportunities are included for illustrative purposes only and should not be construed as endorsements, recommendations, or assurances of specific outcomes, including investment returns or transaction success. 

This material does not constitute an offer to sell or a solicitation to buy any assets or services in jurisdictions where such actions would be unlawful. It is intended solely for the general information of our clients and partners and does not consider the specific investment objectives, financial circumstances, or needs of individual entities, such as those of limited partners (LPs), third-party partners, or other individual investors. The Company is not soliciting any action based on this material, which is provided to underscore our commitment to delivering transformative business development solutions with integrity, strategic foresight, and adherence to global regulatory standards and industry best practices.

Performance Metrics and Reporting Disclaimer

The Company provides performance metrics and reports to clients as part of our business development services, detailing progress on relevant activities such as client acquisition, partnership negotiations, and vendor coordination for their pharmaceutical assets. These reports are based on our professional judgment and available data, which we believe to be reliable but not independently verified. We disclaim liability for inaccuracies or decisions made in reliance on these metrics, as outcomes may vary due to market or regulatory conditions. We are committed to delivering timely and transparent updates, adhering to global regulatory standards and industry best practices. 

Transfer of Value and Healthcare Organization Disclosure Statement

Pursuant to global regulatory standards and the applicable transparency codes (e.g., EFPIA Code of Practice, U.S. Sunshine Act), the Company supports the disclosure of transfers of value (ToV) to healthcare organizations (HCOs) or healthcare professionals (HCPs) where such transfers occur within client engagements. Our clients acknowledge our Company’s ToV disclosures policy and assume full responsibility for the accuracy and timeliness of all ToV disclosures. The Company expressly disclaims liability for any inaccuracies, omissions, or non-compliance in client-driven ToV disclosures, including those arising from market, regulatory, or other external factors.

For inquiries or to report concerns, please email us at compliance@charisisandco.com